For Health Care Professionals Outside the US

 
 
 

Appropriate patients for FARYDAK regimen


FARYDAK® (panobinostat) regimen may be an appropriate choice for your adult patients with relapsed and/or refractory multiple myeloma who previously received at least 2 prior regimens, including bortezomib (BTZ) and an immunomodulatory drug (IMiD)1

Appropriate multiple myeloma patients for FARYDAK.
  • When considering whether or not a patient is appropriate for FARYDAK regimen, it is important to consider individual response to prior therapy
  • For patients who have had a positive experience with BTZ + dexamethasone (dex)—had a good first response (achieved ≥PR), manageable toxicity, and relapsed after a fixed number of BTZ cycles—it may be beneficial to treat with FVD regimen
  • Consider adding FARYDAK to maximise the clinical potential of BTZ/dex

Deciding if a patient is right for FARYDAK regimen

Consider John’s multiple myeloma journey:
John
My response to BTZ was good.
After my first relapse, I was treated to progression with an IMiD. I was able to stay in remission for a while, but now I’ve relapsed.
What more can I do?
 

  • 62-year-old male
  • Has mild renal impairment
  • Received autologous stem cell transplantation (ASCT)
  • Achieved ≥PR with first-line treatment of BTZ/dex

FVD regimen may be appropriate for relapsed patients like John

FVD regimen may be appropriate if your patient had:

  • A good response to BTZ (achieved ≥PR) and relapsed after a fixed number of cycles
  • Manageable toxicity
  • Prior treatment with an IMiD

Reference:

  1. FARYDAK® (panobinostat). EU Summary of Product Characteristics. Novartis AG; April 2016.

Ready to prescribe? Create a custom medicine tracker calendar for your patient